Final Professional MBBS — Ophthalmology (complete, 12 chapters). Explanation-first answers with anatomical, optics, neuro & public-health diagrams, classifications, comparison tables, drug doses, clinical pearls and key-point recaps from Khurana's Comprehensive Ophthalmology, Parsons' Diseases of the Eye and Park's PSM.
12chapters144questions39High-Yield
THE CONCEPT
Diabetic retinopathy is a microvascular complication of diabetes mellitus and a leading cause of blindness in working-age adults. Chronic hyperglycaemia damages the retinal capillaries, and the risk rises with the duration of diabetes and poor glycaemic control (and with hypertension, nephropathy and pregnancy).
Optic disc
Macula & fovea
Arteries (thin, bright)
Veins (wide, dark)
The normal fundus: the pale optic disc (nasally) with vessels emerging and arcading around the darker macula, whose centre is the fovea. Arteries are thinner and brighter, veins wider and darker.
PATHOGENESIS
Hyperglycaemia causes capillary basement-membrane thickening, loss of pericytes and endothelial damage. This leads to microaneurysms and increased permeability (oedema and exudates), and to capillary occlusion and retinal ischaemia. The ischaemic retina then releases VEGF, which drives new-vessel formation (neovascularisation) — the dangerous, proliferative stage.
CLASSIFICATION
Non-proliferative DR (NPDR) — microaneurysms, dot-and-blot haemorrhages, hard exudates, cotton-wool spots, venous beading and IRMA; graded mild, moderate or severe.
Proliferative DR (PDR) — neovascularisation (of the disc, NVD, or elsewhere, NVE), which can bleed (vitreous haemorrhage), scar and pull (tractional retinal detachment), or cause neovascular glaucoma.
Diabetic maculopathy — macular oedema, exudates or ischaemia; it can occur at any stage and is the commonest cause of visual loss.
Neovascular / dot-blot
haemorrhages (dark)
Hard exudates (yellow)
Cotton-wool spots (white)
Signs of diabetic retinopathy: microaneurysms and dot-and-blot haemorrhages (dark red), hard exudates (yellow, often ringing the macula), cotton-wool spots (fluffy white), and fine new vessels (neovascularisation) at the disc.
MANAGEMENT
Systemic control — tight glycaemic, blood-pressure and lipid control is the foundation.
Maculopathy — anti-VEGF injections (first-line for centre-involving macular oedema), focal laser, or steroids.
PDR — pan-retinal photocoagulation (PRP) (laser to the ischaemic retina reduces the VEGF drive), anti-VEGF, and vitrectomy for non-clearing vitreous haemorrhage or tractional detachment.
Screening — annual dilated retinal screening for all diabetics, since early disease is asymptomatic.
💡
CLINICAL PEARL: Diabetic retinopathy is a microvascular disease progressing from NPDR (microaneurysms, dot-blot haemorrhages, hard exudates, cotton-wool spots, venous beading, IRMA) to PDR (neovascularisation → vitreous haemorrhage, tractional RD, neovascular glaucoma). Maculopathy is the commonest cause of visual loss. Control sugar, BP and lipids; give anti-VEGF for macular oedema and PRP for PDR; and screen every diabetic annually.
UNDERSTANDING THE LESIONS
Each fundus sign in diabetic retinopathy corresponds to a step in the microvascular pathology, and understanding this makes them easy to remember. Microaneurysms are the earliest sign — tiny outpouchings of weakened capillaries. Dot-and-blot haemorrhages are deeper, rounded bleeds within the retina, while hard exudates are yellow deposits of leaked lipid at the edge of areas of oedema. Cotton-wool spots are not exudates at all but micro-infarcts of the nerve-fibre layer (a sign of ischaemia), and venous beading and intraretinal microvascular abnormalities (IRMA) mark severe ischaemia that heralds proliferation. Reading these signs together lets the clinician judge how close the eye is to the dangerous proliferative stage.
WHY MACULOPATHY MATTERS MOST
Although proliferative disease is the most dramatic, it is diabetic maculopathy that causes the most visual loss overall, and it can occur at any stage — even with otherwise mild retinopathy. The macula is responsible for central, detailed vision, so oedema, exudate or ischaemia there directly blurs reading vision. This is why every diabetic eye assessment specifically examines the macula (with OCT to detect and measure oedema), and why anti-VEGF injections targeting the macula have become the first-line treatment for centre-involving diabetic macular oedema. Recognising that maculopathy and proliferative disease are two separate threats — needing different treatments — is central to managing diabetic eye disease.
A NOTE ON PREVENTION & THE VALUE OF SCREENING
The single most effective measure against blindness from diabetic retinopathy is systematic screening combined with good systemic control. Because sight-threatening disease is asymptomatic until late, a diabetic can lose a large amount of vision before noticing anything, by which time treatment is less effective. Annual dilated retinal screening (increasingly with retinal photography) detects treatable disease early, and landmark trials showed that tight glycaemic and blood-pressure control markedly reduces progression. This is why diabetic retinopathy is regarded as a largely preventable cause of blindness, and why every diabetic is enrolled in regular screening from diagnosis — the treatment of an established complication being far less satisfactory than preventing it.
💊
KEY POINTS / NUMBERS (viva)
Diabetic retinopathy = microvascular; leading cause of blindness in working-age adults; risk ∝ duration + control (+ HTN, nephropathy, pregnancy).
Maculopathy = commonest cause of vision loss; control glucose/BP/lipids; anti-VEGF for DMO; PRP for PDR; vitrectomy for non-clearing VH/tractional RD; annual screening.
🔑
KEY POINTS TO REMEMBER
Diabetic retinopathy = microvascular complication of diabetes; leading cause of blindness in working-age adults.
Diabetic maculopathy (oedema/exudates/ischaemia) is the commonest cause of visual loss; assess with OCT and fluorescein angiography.
Control glucose/BP/lipids; anti-VEGF for macular oedema; PRP for PDR; vitrectomy for non-clearing VH/tractional RD; screen all diabetics annually.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Parsons' Diseases of the Eye.
THE CONCEPT
Retinal detachment is separation of the neurosensory retina from the underlying retinal pigment epithelium (RPE), with fluid accumulating in the subretinal space. Because the photoreceptors depend on the RPE and choroid for nourishment, a detached retina rapidly loses function, making this a sight-threatening emergency — especially when the macula is threatened.
Detached retina
Subretinal fluid
Retinal break (tear)
Sclera
Choroid + RPE
Rhegmatogenous retinal detachment: liquefied vitreous passes through a retinal break (horseshoe tear) and lifts the neurosensory retina off the underlying retinal pigment epithelium, with subretinal fluid collecting beneath it.
TYPES
Rhegmatogenous (the commonest) — a retinal break/tear lets liquefied vitreous pass under the retina. Risk factors: high myopia, aphakia/pseudophakia, trauma, lattice degeneration, posterior vitreous detachment and a family history.
Tractional — fibrovascular membranes pull the retina off (proliferative diabetic retinopathy, retinopathy of prematurity, trauma).
Exudative (serous) — fluid leaks under the retina without a break (intraocular tumours such as choroidal melanoma/metastases, inflammation, VKH, severe hypertension/eclampsia).
SYMPTOMS & SIGNS
The classic symptoms are the sudden onset of floaters and flashes of light (photopsia), followed by a 'curtain' or shadow spreading across the field of vision, and central visual loss if the macula detaches. Signs include an elevated, grey, folded retina that undulates, a visible break, 'tobacco dust' (Shafer's sign — pigment in the vitreous), a lower intraocular pressure and an RAPD if the detachment is extensive.
MANAGEMENT
Rhegmatogenous detachment needs urgent surgery to seal the break(s) and reappose the retina: retinopexy (laser or cryotherapy) combined with a scleral buckle, pneumatic retinopexy, or pars plana vitrectomy with gas or silicone-oil tamponade. A 'macula-on' detachment is a surgical emergency — repairing it before the macula detaches gives the best visual outcome. Tractional and exudative detachments are managed by treating the underlying cause (vitrectomy for traction; systemic treatment for exudative).
💡
CLINICAL PEARL: Retinal detachment is separation of the neurosensory retina from the RPE. The rhegmatogenous type (from a break) is commonest — think floaters, flashes and a curtain, with risk from myopia, aphakia, trauma and lattice. Tractional (PDR/ROP) and exudative (tumour/inflammation, no break) are the others. A macula-on detachment is an emergency; treat with retinopexy plus buckle/vitrectomy/pneumatic retinopexy. Remember Shafer's sign (tobacco dust).
THE WARNING SYMPTOMS & WHY THEY MATTER
The symptoms of retinal detachment follow a recognisable, teachable sequence that provides a vital early-warning system. Flashes (photopsia) come from vitreous traction stimulating the retina, and a shower of new floaters from a posterior vitreous detachment or a small vitreous bleed at the moment a tear forms. If a tear then allows fluid under the retina, the patient sees a dark 'curtain' or shadow advancing across the field from the periphery. The crucial teaching point is that a retinal tear treated with laser before it progresses to detachment can prevent the detachment entirely — so any patient with new flashes and floaters needs an urgent dilated examination, and this simple advice can save sight.
MACULA-ON VERSUS MACULA-OFF
A concept that governs the urgency of surgery is whether the detachment is 'macula-on' or 'macula-off'. While the detachment spares the macula (macula-on), central vision is still normal, and urgent repair can preserve it — so these are operated as an emergency, often within a day. Once the macula has detached (macula-off), central vision is already lost and, although surgery still reattaches the retina, the recovery of central acuity is often incomplete, so the same few-hours' urgency no longer applies. This distinction explains why the history of whether and when central vision was affected is so important, and why it drives the timing of surgery.
A NOTE ON THE ROLE OF ULTRASOUND & EXAMINATION
In diagnosing retinal detachment, careful examination technique is decisive. The whole retina must be inspected with indirect ophthalmoscopy and scleral indentation to find every break (a detachment cannot be reliably repaired unless all breaks are found and sealed). When the view is obscured — by a vitreous haemorrhage or dense cataract — a B-scan ultrasound demonstrates the detached, mobile retina and any associated pathology such as a tumour or a large tear. This emphasis on finding and localising the breaks explains why detachment surgery is meticulous and why the pre-operative examination is as important as the operation itself in determining success.
Sudden floaters + flashes (photopsia) + a 'curtain'; grey folded mobile retina, visible break, Shafer's sign (tobacco dust), low IOP.
Macula-on = surgical emergency; retinopexy (laser/cryo) + scleral buckle / pneumatic retinopexy / vitrectomy + gas or silicone-oil tamponade.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Occlusion of the retina's central artery or vein causes sudden, painless loss of vision and is a common cause of acute monocular visual loss. Central retinal artery occlusion (CRAO) is an ophthalmic emergency (the inner retina is highly sensitive to ischaemia), while central retinal vein occlusion (CRVO) is important for its complications.
CRAO
pale retina + cherry-red spot
CRVO
'blood & thunder' haemorrhages
Retinal vascular occlusions. CRAO: a pale, oedematous retina with a cherry-red spot at the fovea. CRVO: the 'blood-and-thunder' fundus of widespread haemorrhages in all quadrants with dilated, tortuous veins and a swollen disc.
CENTRAL RETINAL ARTERY OCCLUSION
CRAO is usually embolic (from carotid or cardiac sources) or thrombotic, and in the elderly may be caused by giant cell arteritis. It presents with sudden, painless, profound monocular visual loss. Signs are a pale, oedematous retina with a 'cherry-red spot' at the fovea (where the thin retina lets the choroidal red show through), attenuated arteries with 'cattle-trucking', and a relative afferent pupillary defect (RAPD). Because the retina survives only about 90 minutes, immediate measures (ocular massage, lowering IOP with acetazolamide/paracentesis) are tried, though the prognosis is poor; giant cell arteritis must be excluded (ESR/CRP) and treated with steroids to protect the other eye, and a stroke work-up arranged.
CENTRAL RETINAL VEIN OCCLUSION
CRVO is a thrombosis of the central retinal vein, with risk factors of age, hypertension, glaucoma, diabetes and hyperviscosity. It causes sudden painless visual loss and the classic 'blood-and-thunder' fundus — widespread flame and blot haemorrhages in all four quadrants, dilated tortuous veins, disc swelling and cotton-wool spots. It is divided into non-ischaemic (better prognosis) and ischaemic (RAPD, poor vision, and a risk of neovascular glaucoma — '90-day glaucoma'). Management is to treat risk factors, give anti-VEGF or steroid for macular oedema, and PRP if neovascularisation develops.
💡
CLINICAL PEARL:CRAO = sudden painless monocular loss with a pale retina and cherry-red spot, RAPD — an emergency (massage, lower IOP); it is usually embolic, so exclude giant cell arteritis and work up the carotids/heart. CRVO = the 'blood-and-thunder' fundus (haemorrhages in all quadrants, tortuous veins); the ischaemic type risks neovascular glaucoma. Treat risk factors, anti-VEGF for oedema, PRP for neovascularisation.
A NOTE ON GIANT CELL ARTERITIS
An essential association to remember with CRAO (and with the related anterior ischaemic optic neuropathy) is giant cell (temporal) arteritis. In any patient over 50 with sudden painless visual loss, GCA must be actively excluded because it is a treatable cause that threatens the fellow eye within days. Suggestive features are headache, scalp tenderness, jaw claudication, malaise and a markedly raised ESR and CRP. If GCA is suspected, high-dose systemic corticosteroids are started immediately — before biopsy confirmation — to protect the second eye. Missing this diagnosis is a classic and serious error, which is why inflammatory markers are checked urgently in every older patient with an arterial occlusion or ischaemic optic neuropathy.
BRANCH OCCLUSIONS & THE COMMON PRINCIPLE
It is worth noting that the central vessels are not the only ones that occlude: branch retinal artery and vein occlusions (BRAO/BRVO) are common and affect only the sector of retina supplied by the blocked branch, causing a corresponding partial (altitudinal or sectoral) field defect rather than total loss. BRVO in particular is very common (often at an arteriovenous crossing in a hypertensive patient) and, like CRVO, is managed by treating risk factors, anti-VEGF for macular oedema and laser for neovascularisation. The unifying principle across all these occlusions is that the pattern of visual loss maps onto the territory of the blocked vessel, and that the underlying vascular risk factors must always be sought and treated.
A NOTE ON THE UNDERLYING SYSTEMIC ASSESSMENT
A crucial message common to both occlusions is that they are frequently markers of systemic vascular disease, so the eye finding should trigger a systemic work-up. CRAO is essentially a 'stroke of the eye' — an embolic event demanding urgent assessment of the carotid arteries and heart, and of vascular risk factors, exactly as for a cerebral transient ischaemic attack, because the patient is at high risk of a subsequent stroke. CRVO points to hypertension, diabetes, glaucoma and, in younger patients, hyperviscosity or thrombophilia. Treating the eye without addressing these underlying conditions misses the chance to prevent a future, potentially fatal, vascular event — which is why these occlusions are managed jointly with physicians.
CRVO ischaemic type → neovascular glaucoma ('90-day'); treat risk factors, anti-VEGF/steroid for macular oedema, PRP for neovascularisation.
📚
SOURCES: Khurana's Comprehensive Ophthalmology; Parsons' Diseases of the Eye.
THE CONCEPT
Retinitis pigmentosa (RP) is a group of inherited, progressive retinal dystrophies characterised by primary degeneration of the photoreceptors (the rods first) and the retinal pigment epithelium. It is the commonest inherited retinal degeneration, is bilateral, and slowly progresses over years toward severe visual loss.
INHERITANCE
RP may be autosomal dominant (usually milder), autosomal recessive, or X-linked (usually severe), and may occur as part of a syndrome — Usher syndrome (with sensorineural deafness), Bardet–Biedl and Refsum disease.
CLINICAL FEATURES
Because the rods degenerate first, the earliest symptom is night blindness (nyctalopia), followed by progressive loss of the peripheral field, giving 'tunnel vision', and eventually reduced central acuity. The classic fundus triad is:
Bone-spicule pigmentation in the mid-peripheral retina.
Attenuated (narrowed) retinal arterioles.
A waxy, pale optic disc.
Associated findings include posterior subcapsular cataract, cystoid macular oedema and vitreous cells.
INVESTIGATION & MANAGEMENT
The key diagnostic test is the electroretinogram (ERG), which is reduced or extinguished; visual fields show progressive constriction, and OCT and genetic testing help. There is no definitive cure; management is supportive — genetic counselling, low-vision aids, treatment of cystoid macular oedema (acetazolamide) and cataract, with emerging gene therapy (e.g. voretigene neparvovec for RPE65 mutations) and retinal implants.
💡
CLINICAL PEARL: Retinitis pigmentosa is an inherited, progressive rod–cone dystrophy: it begins with night blindness and progresses to tunnel vision. Recognise the triad — bone-spicule pigmentation, attenuated arterioles and a waxy pale disc — and that the ERG is reduced/extinguished (diagnostic). Look for Usher syndrome (with deafness). Care is supportive, with gene therapy now emerging for specific genotypes.
A NOTE ON THE ELECTRORETINOGRAM
The electroretinogram (ERG) deserves emphasis as the key objective test in retinitis pigmentosa. It records the electrical response of the retina to light, and in RP it is characteristically reduced or extinguished, with the rod responses affected earliest and most severely — mirroring the rod-first degeneration. Importantly, the ERG can be abnormal before obvious fundus changes appear, allowing early diagnosis, and it helps distinguish RP from conditions that merely resemble it. This makes the ERG central both to confirming the diagnosis and to understanding the disease as a primary photoreceptor disorder rather than a problem of the optic nerve or higher pathways.
A NOTE ON THE SYNDROMIC ASSOCIATIONS
Because retinitis pigmentosa can be part of a systemic syndrome, its diagnosis should prompt a wider assessment. The most important is Usher syndrome — RP combined with sensorineural deafness — the commonest cause of combined deaf-blindness, in which early identification allows crucial communication and educational support for the child. Others include Bardet–Biedl syndrome (with obesity, polydactyly, renal disease and learning difficulty) and Refsum disease (a treatable disorder of phytanic-acid metabolism). Recognising these associations matters because some have treatable systemic components and all benefit from genetic counselling, so a child diagnosed with RP is assessed for hearing and other systemic features rather than for the eyes alone.
A NOTE ON THE PROGNOSIS & SUPPORT
Because there is as yet no cure for most forms, an important part of managing retinitis pigmentosa is honest counselling and practical support. The disease is slowly progressive over decades, and although many patients retain some central vision into middle age or beyond, the gradual loss of the field is disabling (affecting mobility and night driving especially). Care therefore includes low-vision rehabilitation, mobility training, occupational and educational support, and genetic counselling for the patient and family. The recent arrival of gene therapy for specific mutations (such as RPE65) and of retinal prostheses offers realistic hope for some, which is why accurate genetic diagnosis is increasingly important — both to guide prognosis and to identify those who might benefit from emerging treatments.
A NOTE ON DISTINGUISHING RP FROM ITS MIMICS
An important clinical skill is separating true retinitis pigmentosa from conditions that can produce a similar 'pigmentary retinopathy'. Pigment changes resembling RP can follow previous inflammation or infection (e.g. congenital rubella or syphilis), drug toxicity (such as chloroquine or phenothiazines), and trauma, and there are related inherited conditions such as cone-rod dystrophy (in which cones and central vision are affected first, the reverse of RP) and Leber congenital amaurosis (a severe infantile form). The pattern of the ERG, the symmetry and progression, the family history, and the associated features help distinguish genuine, primary RP from these acquired mimics — a distinction that matters because some mimics are treatable or preventable, whereas primary RP is managed supportively.
Night blindness (nyctalopia) earliest → progressive peripheral field loss (tunnel vision) → reduced central acuity.
Fundus triad: bone-spicule pigmentation, attenuated arterioles, waxy pale optic disc; plus PSC cataract and cystoid macular oedema.
ERG reduced/extinguished is the key diagnostic test; inheritance AD/AR/X-linked; syndromic (Usher with deafness, Bardet-Biedl, Refsum).
No cure; supportive (genetic counselling, low-vision aids, treat CMO/cataract); emerging gene therapy (voretigene for RPE65) and retinal implants.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Retinoblastoma is the commonest primary intraocular malignancy of childhood, arising from primitive retinal cells. It is caused by mutation of the RB1 tumour-suppressor gene (chromosome 13) and is life-threatening as well as sight-threatening, so early diagnosis is critical.
Normal
dark pupil / red reflex
Leukocoria
white pupil → retinoblastoma
Leukocoria — a white pupillary reflex replacing the normal red reflex — is the commonest presenting sign of retinoblastoma and always demands urgent assessment to exclude this life-threatening tumour.
GENETICS
Both copies of the RB1 gene must be lost (Knudson's 'two-hit' hypothesis). In the hereditary (germline) form (~40%) the tumours are typically bilateral and multifocal, present younger, and carry a lifelong risk of second cancers (notably osteosarcoma); the sporadic form is unilateral.
PRESENTATION
It usually presents before the age of 3 years with:
Leukocoria (a white pupillary reflex) — the commonest presenting sign.
Strabismus (squint) — the second commonest.
Less often a red, painful eye, proptosis (advanced disease) or poor vision.
The differential of leukocoria includes congenital cataract, retinopathy of prematurity, Coats disease, toxocariasis and persistent hyperplastic primary vitreous.
INVESTIGATION & MANAGEMENT
Diagnosis is by examination under anaesthesia and imaging — ultrasound/CT show characteristic calcification, and MRI assesses optic-nerve and CNS spread. Biopsy is contraindicated (risk of tumour seeding). Treatment depends on size and laterality: chemotherapy (systemic or intra-arterial) to shrink the tumour plus focal therapy (laser, cryotherapy, plaque), and enucleation (with a long optic-nerve stump) for advanced disease; external-beam radiotherapy is avoided where possible (it induces second tumours). Genetic counselling and screening of the family are essential, and the prognosis is good if the tumour is intraocular and treated early.
💡
CLINICAL PEARL: Retinoblastoma is the commonest childhood intraocular malignancy, from the RB1 gene (chromosome 13, two hits). A child under 3 with leukocoria (commonest sign) or a squint must be assumed to have it until proven otherwise. Hereditary disease is bilateral (germline, second cancers); sporadic is unilateral. CT shows calcification; never biopsy. Treat with chemotherapy + focal therapy or enucleation, and give genetic counselling.
THE HEREDITARY FORM & SECOND CANCERS
A point of great importance is the distinction between the hereditary and sporadic forms, because it affects the whole family. In the hereditary (germline) form, the child carries an RB1 mutation in every cell of the body, which is why the tumours are typically bilateral and multifocal, present earlier, and — crucially — why these children have a lifelong, greatly increased risk of second, non-ocular cancers (especially osteosarcoma, and others in later life). This germline mutation is heritable, so siblings and future children are at risk. These facts make genetic testing and counselling essential: they identify affected relatives who need screening, guide surveillance for second tumours, and inform reproductive decisions — turning retinoblastoma from a single-eye problem into a family and lifelong concern.
WHY BIOPSY IS AVOIDED & HOW DIAGNOSIS IS MADE
A distinctive principle in retinoblastoma is that, unlike most tumours, it is diagnosed without a biopsy. Breaching the eye to sample the tumour risks seeding malignant cells into the orbit and beyond, converting a curable intraocular tumour into a lethal one. Instead the diagnosis is made on the characteristic clinical appearance under anaesthesia together with imaging — ultrasound and CT demonstrating intraocular calcification (a hallmark of retinoblastoma), and MRI assessing spread along the optic nerve and into the brain. This reliance on clinical and imaging diagnosis, and the avoidance of biopsy, is a defining feature of the condition and explains the emphasis on examination under anaesthesia by an experienced ocular oncologist.
A NOTE ON MANAGEMENT & EYE-PRESERVING TREATMENT
Modern management of retinoblastoma has shifted strongly toward preserving the eye and vision where it is safe to do so, reserving enucleation for advanced tumours. Small and medium tumours are increasingly controlled with chemotherapy to shrink the tumour ('chemoreduction') followed by focal 'consolidation' treatments — laser photocoagulation, cryotherapy or a radioactive plaque — and, in selected cases, intra-arterial or intravitreal chemotherapy that delivers the drug directly to the eye. External-beam radiotherapy is now avoided where possible, particularly in the hereditary form, because it further increases the already-high risk of second cancers. Throughout, the guiding priorities are, in order, saving the child's life, then the eye, then the vision — a hierarchy that shapes every treatment decision and is explained carefully to the family.
💊
KEY POINTS / NUMBERS (viva)
Retinoblastoma = commonest childhood intraocular malignancy; RB1 gene (chr 13), Knudson two-hit; usually presents < 3 years.
Leukocoria (commonest sign) + strabismus (2nd); hereditary (~40%, germline, bilateral/multifocal, 2nd cancers e.g. osteosarcoma) vs sporadic (unilateral).
CT/ultrasound show calcification; NO biopsy (seeding); treat by chemo (systemic/intra-arterial) + focal (laser/cryo/plaque) or enucleation (long optic-nerve stump); genetic counselling + family screening.
🔑
KEY POINTS TO REMEMBER
Retinoblastoma = commonest primary intraocular malignancy of childhood; RB1 tumour-suppressor gene (chr 13), Knudson two-hit; usually < 3 years.
Leukocoria (white pupil) is the commonest sign; strabismus is second; advanced — red painful eye, proptosis.
Hereditary/germline (~40%): bilateral, multifocal, younger, lifelong risk of second cancers (osteosarcoma); sporadic: unilateral.
Treat by chemotherapy + focal therapy (laser/cryo/plaque) or enucleation; avoid external-beam RT if possible; genetic counselling + family screening; good prognosis if intraocular and early.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Age-related macular degeneration (ARMD) is a degeneration of the macula in the elderly and the leading cause of irreversible central visual loss in developed countries. It spares the peripheral field (so patients retain navigational vision) but destroys the central, detailed vision needed for reading and faces.
THE TWO TYPES
Dry (atrophic) ARMD (commoner) — drusen (yellow sub-RPE deposits) and RPE atrophy (geographic atrophy), causing gradual central loss; no curative treatment, though AREDS vitamin supplements slow progression.
Wet (neovascular/exudative) ARMD — choroidal neovascularisation leaks and bleeds, causing rapid central distortion and loss; treated with intravitreal anti-VEGF injections (ranibizumab, aflibercept, bevacizumab).
SYMPTOMS
Patients report a central scotoma and metamorphopsia (distortion — straight lines appear wavy on an Amsler grid), with preserved peripheral vision. Sudden distortion suggests conversion to the wet type and needs urgent referral.
A NOTE ON THE AMSLER GRID & MONITORING
A simple but valuable tool in ARMD is the Amsler grid — a square grid of lines that the patient views one eye at a time. In healthy central vision the lines look straight; in ARMD (especially wet ARMD) they appear wavy, distorted or with a missing patch. Because conversion to wet ARMD is an emergency — early anti-VEGF treatment preserves far more vision than delayed treatment — patients with dry ARMD are given an Amsler grid to check their vision at home and report new distortion immediately. This empowers early detection of the treatable, sight-threatening form and is a good example of patient self-monitoring guiding urgent care.
THE BOTTOM LINE
ARMD destroys central vision in the elderly while sparing the periphery; the dry (atrophic) form is managed with AREDS vitamins and monitoring, while the wet (neovascular) form is a treatable emergency requiring prompt anti-VEGF.
IN PRACTICE
Beyond treatment, the management of ARMD includes important lifestyle and preventive measures: stopping smoking (the strongest modifiable risk factor), a diet rich in leafy greens and fish, and cardiovascular risk-factor control. For the many patients with irreversible central loss, low-vision aids and rehabilitation — magnifiers, high-contrast lighting and reading aids — make a real difference to independence, since the preserved peripheral vision can be used effectively with support.
A further distinction worth making is between ARMD and other maculopathies of the elderly, since not every macular problem in an older patient is ARMD; a careful OCT and history separate it from diabetic maculopathy, macular hole, epiretinal membrane and central serous disease, each of which is managed differently.
🔑
KEY POINTS TO REMEMBER
ARMD = macular degeneration in the elderly; leading cause of irreversible central visual loss (peripheral vision preserved).
Central scotoma + metamorphopsia (Amsler grid distortion); sudden distortion = possible wet conversion → urgent referral.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Hypertensive retinopathy is the group of retinal changes caused by systemic hypertension. The retinal vessels respond to raised blood pressure first by narrowing, then by leaking, and the fundus is a valuable, directly-visible window onto the severity and end-organ effects of the hypertension.
GRADING (Keith–Wagener–Barker)
Grade 1 — mild generalised arteriolar narrowing.
Grade 2 — focal narrowing and arteriovenous nipping (AV nicking), with copper/silver wiring.
Grade 3 — flame haemorrhages, cotton-wool spots and hard exudates (a 'macular star').
Grade 4 — the above plus optic-disc swelling (papilloedema) — this is malignant/accelerated hypertension, an emergency.
SIGNIFICANCE
The retinopathy reflects systemic end-organ damage; management is to control the blood pressure (urgently, but carefully, in grade 4), which allows many changes to regress.
A NOTE ON THE ACUTE (MALIGNANT) PICTURE
It is worth separating the chronic, gradual changes of ordinary hypertensive retinopathy from the dramatic picture of malignant (accelerated) hypertension. Here the blood pressure is severely and rapidly elevated, and the fundus shows bilateral disc swelling, extensive flame haemorrhages, cotton-wool spots and a macular star of hard exudates — grade 4 changes that signify a hypertensive emergency with concurrent damage to the brain, heart and kidneys. This demands urgent but controlled blood-pressure reduction (lowering it too fast can itself harm the optic nerve and brain). Recognising these fundus signs can be the first clue to a life-threatening hypertensive crisis, underlining why fundoscopy is part of assessing the severely hypertensive patient.
THE BOTTOM LINE
Hypertensive retinopathy grades the retinal effects of high blood pressure and, at grade 4, signals a hypertensive emergency; its mainstay of treatment is careful control of the blood pressure.
IN PRACTICE
In interpreting the fundus, it is useful to remember that hypertensive changes overlap with, and can coexist with, arteriosclerotic and diabetic changes, so the picture is read in the light of the patient's age and history. Nonetheless, features such as arteriovenous nipping and copper/silver wiring reflect long-standing hypertension, while fresh haemorrhages, cotton-wool spots and disc swelling indicate active, severe disease needing prompt attention.
It is also useful to grade the retinopathy consistently and record it, because the grade both reflects the chronicity and severity of the hypertension and helps track the response to treatment over time, giving the physician an objective, visible measure of how well the blood pressure is being controlled.
🔑
KEY POINTS TO REMEMBER
Hypertensive retinopathy = retinal changes from systemic hypertension; a visible marker of end-organ damage.
Manage by controlling blood pressure (carefully in grade 4); many changes regress.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Papilloedema is swelling of the optic disc caused specifically by raised intracranial pressure (ICP). The raised pressure is transmitted along the optic-nerve sheath, blocking axoplasmic flow at the disc, which swells. By definition it is bilateral (because ICP affects both nerves).
CAUSES & SIGNS
Causes include intracranial tumours, idiopathic intracranial hypertension, hydrocephalus, meningitis and cerebral venous sinus thrombosis. Signs are blurred, elevated disc margins, absent spontaneous venous pulsation, disc hyperaemia, haemorrhages and cotton-wool spots, and an enlarged blind spot. Crucially, central vision is preserved early (with only transient visual obscurations), but chronic papilloedema causes optic atrophy and permanent visual loss.
MANAGEMENT
Papilloedema mandates urgent neuroimaging to find the cause and treatment directed at lowering the intracranial pressure. It must be distinguished from papillitis (optic-nerve inflammation — usually unilateral, with early visual loss and pain on eye movement).
A NOTE ON PSEUDOPAPILLOEDEMA
A common diagnostic trap is pseudopapilloedema — a disc that looks swollen but is not. The classic cause is optic disc drusen (calcified deposits within the disc), which elevate and blur the disc margins in an otherwise well patient with normal vision and no raised intracranial pressure. Distinguishing true papilloedema from pseudopapilloedema is important to avoid unnecessary alarm and invasive investigation: true papilloedema has hyperaemia, haemorrhages, cotton-wool spots and absent venous pulsation, and is confirmed by finding raised intracranial pressure, whereas drusen can be shown by ultrasound or OCT. Recognising this distinction prevents both missed tumours and needless lumbar punctures.
THE BOTTOM LINE
Papilloedema is bilateral disc swelling from raised intracranial pressure that spares vision early but causes optic atrophy if untreated, mandating urgent neuroimaging and reduction of the pressure.
IN PRACTICE
When papilloedema is confirmed, the urgency of finding the cause cannot be overstated, because it may reflect a life-threatening intracranial mass or venous sinus thrombosis. Neuroimaging is arranged immediately, and only once a mass and venous obstruction are excluded is a lumbar puncture performed (to measure the pressure and diagnose idiopathic intracranial hypertension). This ordered approach — imaging before lumbar puncture — is a standard safety rule to avoid precipitating herniation.
A helpful bedside sign is the loss of spontaneous venous pulsation at the disc, which, although not wholly reliable, tends to disappear as intracranial pressure rises; combined with the other disc changes and the clinical context, it supports the diagnosis while imaging is being arranged.
🔑
KEY POINTS TO REMEMBER
Papilloedema = optic-disc swelling due to raised intracranial pressure; bilateral by definition.
Raised ICP → impaired axoplasmic flow at the disc → swelling; causes: tumour, IIH, hydrocephalus, meningitis, venous sinus thrombosis.
Blurred elevated disc, absent venous pulsation, hyperaemia, haemorrhages, enlarged blind spot; vision preserved early (transient obscurations), optic atrophy if chronic.
Distinguish from papillitis (unilateral, early vision loss, pain); urgent neuroimaging + lower ICP/treat cause.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Vitreous haemorrhage is bleeding into the vitreous cavity. Because the vitreous is normally optically clear, even a small bleed causes prominent symptoms, and a dense bleed causes profound (but often reversible) visual loss and loss of the red reflex.
CAUSES & SYMPTOMS
The commonest cause is proliferative diabetic retinopathy; others are a retinal tear/detachment, retinal vein occlusion, posterior vitreous detachment, trauma, sickle-cell disease, and subarachnoid haemorrhage (Terson syndrome). Patients notice the sudden onset of floaters, 'cobwebs', a red or smoky haze, and — with a dense bleed — sudden painless visual loss.
INVESTIGATION & MANAGEMENT
When the bleed obscures the fundus, a B-scan ultrasound is essential to exclude an underlying retinal tear or detachment. Many haemorrhages clear spontaneously (with observation and head elevation); vitrectomy is needed for non-clearing haemorrhage or to repair an underlying detachment, and PRP treats the proliferative diabetic cause.
A NOTE ON THE OCULAR EMERGENCY IT MAY HIDE
The most important practical point about a vitreous haemorrhage is that it can conceal a sight-threatening retinal tear or detachment behind the blood. Because the fundus cannot be seen directly through a dense bleed, a B-scan ultrasound is mandatory to look for an underlying detachment, and the patient is followed closely. If a detachment is present it must be repaired urgently regardless of the haemorrhage. This is why a vitreous haemorrhage is never simply observed as 'just a bleed' without first excluding a retinal break — a principle that applies especially to a spontaneous haemorrhage in a non-diabetic, where a torn retina is a leading cause.
THE BOTTOM LINE
Vitreous haemorrhage causes sudden floaters and visual loss with a lost red reflex, most often from proliferative diabetic retinopathy, and always requires ultrasound to exclude a hidden retinal detachment.
IN PRACTICE
A practical point is that the appearance and clearance of the haemorrhage depend on its cause and density: a small bleed may clear in days to weeks, while a dense one can take months, and recurrent bleeds suggest ongoing neovascularisation (as in diabetes) that itself needs treatment. Throughout, the priority remains identifying and treating the source of the bleeding and any retinal break rather than simply waiting for the blood to clear.
Because a vitreous haemorrhage in a diabetic usually reflects active proliferative disease, its occurrence is a signal to complete or intensify pan-retinal photocoagulation once the view allows, so that the underlying neovascular drive is treated and further, potentially blinding, bleeds are prevented.
🔑
KEY POINTS TO REMEMBER
Vitreous haemorrhage = bleeding into the vitreous; sudden floaters, haze, painless visual loss, loss of red reflex.
Commonest cause proliferative diabetic retinopathy; also retinal tear/detachment, vein occlusion, PVD, trauma, sickle cell, Terson (subarachnoid).
B-scan ultrasound if the fundus is obscured — exclude an underlying retinal tear/detachment.
Many clear spontaneously (observe, head elevation); vitrectomy for non-clearing bleed or associated RD; PRP for the diabetic cause.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Retinopathy of prematurity (ROP) is a proliferative retinopathy of premature, low-birth-weight infants, and an important, largely preventable cause of childhood blindness. It arises because the retina is incompletely vascularised at premature birth.
PATHOGENESIS & RISK
Hyperoxia (supplemental oxygen) causes the developing retinal vessels to constrict and stop growing; when the infant is later returned to room air the avascular retina becomes hypoxic, releasing VEGF that drives abnormal neovascularisation, which can progress to fibrosis and tractional retinal detachment. Risk factors are prematurity, low birth weight and oxygen therapy.
SCREENING & TREATMENT
At-risk infants are screened by indirect ophthalmoscopy (disease is classified by zone, stage and the presence of 'plus disease'). Treatment of significant disease is laser photocoagulation or anti-VEGF to the avascular retina, with surgery for detachment; careful monitoring of oxygen therapy is the key preventive measure.
A NOTE ON THE HISTORY & THE OXYGEN BALANCE
The story of ROP illustrates a delicate clinical balance. When supplemental oxygen was first used liberally in premature nurseries, an epidemic of blindness ('retrolental fibroplasia') followed; restricting oxygen then reduced ROP but increased deaths and cerebral palsy. Modern practice therefore aims at carefully titrated, monitored oxygen saturations — enough to keep the baby safe, but not so much as to provoke ROP. This history is a classic example of how a well-intentioned treatment can cause harm, and why oxygen in premature infants is now delivered within tight target ranges alongside structured retinal screening, so that both survival and sight are protected.
THE BOTTOM LINE
ROP is a preventable proliferative retinopathy of oxygen-exposed premature infants, controlled by careful oxygen monitoring, structured screening, and laser or anti-VEGF treatment of significant disease.
IN PRACTICE
For completeness, ROP is one of the commonest causes of childhood blindness worldwide, and its burden is greatest where neonatal survival is improving but oxygen delivery and screening are not yet well controlled. This makes establishing structured screening programmes and safe oxygen practices a public-health priority, since timely detection and treatment of significant ROP can prevent a lifetime of blindness in an otherwise healthy child.
In practical terms, the timing of screening is critical and protocol-driven (based on gestational age and birth weight), because the treatable window is narrow; missing it can allow rapid progression to retinal detachment, which is why neonatal units follow strict ROP-screening schedules.
🔑
KEY POINTS TO REMEMBER
ROP = proliferative retinopathy of premature, low-birth-weight infants; major preventable cause of childhood blindness.
Risk: prematurity, low birth weight, oxygen therapy; classified by zone, stage, and 'plus disease'.
Screen at-risk infants (indirect ophthalmoscopy); treat with laser/anti-VEGF to avascular retina; prevent by careful oxygen monitoring.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Central serous retinopathy (CSR) is a localised serous (fluid) detachment of the neurosensory retina at the macula, caused by focal leakage of fluid from the choroid through the retinal pigment epithelium. It classically affects young to middle-aged men, and is associated with psychological stress, 'type-A' personality and corticosteroid use.
FEATURES & INVESTIGATION
Patients notice sudden blurring and dimming of central vision, with metamorphopsia (distortion), micropsia (objects looking smaller), a positive central scotoma and a mild hyperopic shift. Examination shows a round serous elevation at the macula. OCT shows the subretinal fluid, and fluorescein angiography shows a characteristic 'smokestack' or 'ink-blot' leak.
MANAGEMENT
CSR is often self-limiting, resolving over weeks to months. Management is to stop any corticosteroids and reduce stress; focal laser, photodynamic therapy or anti-VEGF are used for persistent or chronic cases.
A NOTE ON THE STEROID CONNECTION
A clinically vital point in CSR is its strong link with corticosteroids — in any form, whether oral, inhaled, nasal, topical or injected, and including endogenous excess (Cushing's) and stress. Steroids can precipitate or worsen CSR and delay its resolution, and turn a self-limiting episode into chronic disease. This has two consequences: when a patient with CSR is found to be taking steroids, stopping or minimising them is often the single most effective treatment; and CSR should be considered before attributing a steroid-treated patient's blurred vision to something else. Recognising this association can resolve the condition simply by removing the offending drug.
THE BOTTOM LINE
Central serous retinopathy is a usually self-limiting macular serous detachment of stressed young men linked to steroids, treated first by removing steroids and reducing stress, with laser/PDT for chronic cases.
IN PRACTICE
Finally, although CSR is usually benign and self-limiting, recurrent or chronic disease can cause permanent RPE damage and lasting visual impairment, so persistent cases are followed and treated actively. A further point is that chronic CSR must be distinguished from wet ARMD or other causes of macular fluid, since the treatments differ — a distinction made on the patient's age, the OCT and angiographic appearance, and the clinical context.
Distinguishing the acute self-limiting form from chronic CSR guides management: an initial episode is usually simply observed after removing steroids and stress, whereas recurrent or persistent subretinal fluid on OCT prompts active treatment to protect the macula from lasting damage.
🔑
KEY POINTS TO REMEMBER
CSR = serous detachment of the neurosensory retina at the macula from focal RPE/choroidal leakage.
Typically young/middle-aged men; associated with stress, type-A personality, corticosteroid use.
Blurred/dim central vision, metamorphopsia, micropsia, positive scotoma, hyperopic shift; OCT shows subretinal fluid, FFA shows 'smokestack'/'ink-blot' leak.
Often self-limiting (weeks–months); stop steroids, reduce stress; focal laser/PDT/anti-VEGF if persistent or chronic.
📚
SOURCES: Khurana's Comprehensive Ophthalmology.
THE CONCEPT
Posterior vitreous detachment (PVD) is separation of the posterior vitreous cortex from the retina. It happens with age as the vitreous gel liquefies (syneresis) and collapses, pulling away from the retinal surface. It is very common and usually benign, but it matters because of what it can trigger.
SYMPTOMS & SIGNIFICANCE
The typical symptoms are the sudden onset of floaters — classically a ring-shaped floater (Weiss ring, from the vitreous detaching around the optic disc) — and flashes of light (photopsia) from traction on the retina. The importance is that where the vitreous is firmly adherent, this traction can tear the retina, causing a retinal break, retinal detachment or vitreous haemorrhage.
MANAGEMENT
Because of this risk, every acute PVD needs a careful dilated fundus examination to exclude a retinal break (looking for 'tobacco dust'). If no break is found the patient is reassured and warned of the symptoms of retinal detachment; any retinal tear is treated promptly with laser.
A NOTE ON WHY 'FLASHES & FLOATERS' ALWAYS NEED EXAMINATION
The key clinical teaching from PVD is the rule that new flashes and floaters must always be taken seriously. Although most PVDs are benign, a proportion are accompanied by a retinal tear, and the only way to tell them apart is a dilated fundus examination. Warning signs of a tear or developing detachment include a sudden shower of many floaters, persistent flashes, 'tobacco dust' in the vitreous, or a shadow/curtain in the field. Patients are therefore examined promptly and, even when no break is found, are counselled to return immediately if these warning symptoms appear — a simple safety net that catches the minority of PVDs that go on to threaten sight.
THE BOTTOM LINE
Posterior vitreous detachment is a common, usually benign age-related event, but because its traction can tear the retina, every acute case needs a dilated examination to exclude a break.
IN PRACTICE
It is also worth appreciating that a PVD, once complete, generally settles with time as the brain adapts to the persistent floater, and most patients need only reassurance. The clinical effort is therefore concentrated on the initial assessment to catch the dangerous minority, after which management is largely conservative — a good example of matching the intensity of investigation to the (small but serious) risk rather than to the (common and benign) symptom.
Ultimately, PVD is best thought of as a common, benign event carrying a small but important risk, and the whole clinical approach — prompt examination followed by reassurance or laser — is designed to separate the many who need nothing from the few whose retina is torn.
🔑
KEY POINTS TO REMEMBER
PVD = separation of the posterior vitreous from the retina as the gel liquefies (syneresis) and collapses with age; common, usually benign.
Sudden floaters (classically a Weiss ring) and flashes (photopsia) from retinal traction.
Traction at firm adhesions can cause a retinal tear/detachment or vitreous haemorrhage.
Every acute PVD needs a dilated fundus exam to exclude a break (look for tobacco dust); reassure if none, treat any tear with laser, warn of RD symptoms.